
    
      A Phase II, open-label randomized, multicenter trial to compare nab-paclitaxel in combination
      with gemcitabine verus S1 with gemcitabine with respect to overall survival, objective tumor
      response rate and Progression Free Survival (PFS) in patients diagnosed with locally advanced
      or metastatic adenocarcinoma of the pancreas.
    
  